Karyopharm Therapeutics | KPTI - Ativos





Ativos Alterar Data
AbbVie USD 147.68B 12.57B 2026-09
Abbott USD 108.25B 968M 2026-09
Amgen USD 96.05B 409M 2026-09
AstraZeneca USD 119.92B 4.09B 2026-09
BioCryst Pharmaceuticals USD 591.07M 33.22M 2026-09
Bristol-Myers Squibb USD 88.77B 1.14B 2026-09
Eli Lilly USD 148.07B 5.79B 2026-09
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
GlaxoSmithKline GBP 71.7B 9.96B 2026-09
Incyte USD 7.29B 585.39M 2026-09
J&J USD 197.42B 3.64B 2026-09
Karyopharm Therapeutics USD 131.42M 23M 2026-03
MacroGenics USD 345.41M 127.54M 2026-06
Merck USD 132.77B 2.97B 2026-09
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Novartis USD 117.15B 4.88B 2026-09
Novartis USD 117.15B 1.38B 2026-09
Pfizer USD 204.54B 3.41B 2026-09
Regeneron Pharmaceuticals USD 44.41B 2.67B 2026-09
Roche Holding CHF 98.2B 2.5B 2026-06
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Takeda JPY 15.27T 391.77B 2026-09
Tectonic Therapeutic USD 237.03M 9.54M 2026-06
TG Therapeutics USD 1.64B 110.79M 2026-06
Ultragenyx Pharmaceutical USD 1.19B 77M 2026-09
Xencor USD 770.5M 45.54M 2026-09